Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Horby, Peter, Mafham, Marion, Linsell, Louise, Bell, Jennifer L, Staplin, Natalie, Emberson, Jonathan R, Wiselka, Martin, Ustianowski, Andrew, Elmahi, Einas, Prudon, Benjamin, Whitehouse, Tony, Felton, Timothy, Williams, John A, Faccenda, Jakki, Underwood, Jonathan, Baillie, J Kenneth, Chappell, Lucy C, Faust, Saul N, Jaki, Thomas, Jeffery, Katie, Lim, Wei Shen, Montgomery, Alan, Rowan, Kathryn, Tarning, Joel, Watson, James A, White, Nicholas J, Juszczak, Edmund, Haynes, Richard and Landray, Martin J (2020) Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine. ISSN 1533-4406. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://www.nejm.org/doi/10.1056/NEJMoa2022926?url...

Abstract

BACKGROUND

Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.

METHODS

In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality.

RESULTS

The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.

CONCLUSIONS

Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QV Pharmacology
WC Communicabable diseases
Divisions: Clinical Support > Critical Care
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 16 Oct 2020 15:58
Last Modified: 16 Oct 2020 15:58
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3552

Actions (login required)

View Item View Item